Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Bloomberg Customers


February 13, 2016 9:47 PM ET

Biotechnology

Company Overview of AbGenomics International, Inc.

Company Overview

AbGenomics International, Inc., a biopharmaceutical company, focuses on the discovery and development of antibody therapeutics for the treatment of cancer and immune related inflammatory diseases. It offers AbGn-168, an immunomodulating investigational therapeutic antibody against CD162 that induces apoptosis of late-stage activated T cells and other immune cells, as well as spare naive, regulatory, and memory T cells; various animal disease models, such as CIA, NOD, and allergy, as well as transplantation rejection/GVHD in murine and DTH in non-human primate; and autoimmune diseases, including rheumatoid arthritis, Crohn's disease, lupus, and psoriasis. The company also provides antibody-7 ...

4984 El Camino Real

Suite 100

Los Altos, CA 94022

United States

Founded in 2000

Phone:

650-988-9912

Fax:

650-988-9913

Key Executives for AbGenomics International, Inc.

Founder, Chairman of the Board and Chief Executive Officer
Director of Operation, Corporate Secretary and Director
Director of IP Management & Quality Assurance
Director of Project & Alliance Managements
Chief Scientific Officer
Compensation as of Fiscal Year 2015.

AbGenomics International, Inc. Key Developments

AbGenomics International, Inc. Presents at 14th Annual BIO Investor Forum, Oct-21-2015 10:00 AM

AbGenomics International, Inc. Presents at 14th Annual BIO Investor Forum, Oct-21-2015 10:00 AM. Venue: Parc 55 Hotel, San Francisco, California, United States.

AbGenomics International Announces Initiation of Phase-Ib/IIa Clinical Trial of Neihulizumab (AbGn-168H) for the Treatment of Steroid Refractory Acute GvHD (aGvHD)

AbGenomics International announced the start of a phase-Ib/IIa clinical trial using the lead compound Neihulizumab (AbGn-168H) to treat steroid refractory acute GvHD (aGvHD). This investigator-initiated trial is sponsored by Stanford University in its bone marrow transplant program. The primary objective of the study is to evaluate the safety and efficacy of AbGn-168H in patients with steroid refractory aGvHD in the post-allogeneic transplantation setting. aGVHD is a major complication of hematopoietic cell transplantation (HCT) that accounts for most non-relapse mortality and limits the use of HCT. Steroid refractory aGVHD carries an especially high mortality of between 60-85%. According to key opinion leaders in this field, a huge unmet medical need of aGvHD needs to be satisfied under the existing therapies. Prior to the aGvHD trial, the proof of clinical efficacy and safety of AbGn-168H, a humanized monoclonal antibody, has been well demonstrated in a randomized, multicenter, double-blind, placebo-controlled phase II trial in patients with moderate-to-severe plaque psoriasis. Most recently, AbGenomics has also initiated an open-label, multi-center phase II study for psoriatic arthritis. The company is dedicated to bring forth this potential game-changing therapeutic candidate for the treatment of various inflammatory diseases.

AbGenomics International, Inc. Presents at 13th Annual BIO Investor Forum, Oct-08-2014 02:30 PM

AbGenomics International, Inc. Presents at 13th Annual BIO Investor Forum, Oct-08-2014 02:30 PM. Venue: The Palace Hotel, San Francisco, CA 94105, United States.

Similar Private Companies By Industry

Company Name Region
Iguazu Biosciences Corp. United States
Mimedx, Inc. United States
Angion Biomedica Corp. United States
GeneVivo LLC United States
Applied Biotherapeutics, LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact AbGenomics International, Inc., please visit www.abgenomics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.